Call Us Today:  617-277-5000 Patient Portal Login

Publications

The physicians at MHB are world leaders in men’s health research.

Below are several publications by MHB physicians that are widely cited in the medical literature


To open the article pdf in new browser window, click the title.
To download and save article, right-click and chose “Save As..”.

2014 – Death by Testosterone – We Think Not
2014 – Testosterone, Cardiovascular Risk, and Hormonophobia
2014 – Who Is a Candidate for Testosterone Therapy – a Synthesis of International Expert Opinions
2011 – Testosterone Deficiency
2009 – Testosterone Therapy in Men With Prostate Cancer – Scientific and Ethical Considerations


Clinical research by Dr. Morgentaler and his physicians – links to abstracts on PubMed:

Click the titles below to slide open/close the accordions.

Will I have a heart attack or stroke if I take testosterone therapy?
Morgentaler A.
J Sex Med. 2014 Jun;11(6):1601-2. No abstract available.

Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation.
Morgentaler A, Lunenfeld B.
Aging Male. 2014 Jun;17(2):63-5. Epub 2014 May 6. No abstract available.

Does Testosterone Increase the Risk of a Cardiovascular Event?
Seftel AD, Morgentaler A.
J Urol. 2014 Apr 16. No abstract available.

Deaths and cardiovascular events in men receiving testosterone.
Morgentaler A, Traish A, Kacker R.
JAMA. 2014 Mar 5;311(9):961-2. No abstract available.

Andrology: Testosterone and cardiovascular risk – deciphering the statistics.
Morgentaler A, Kacker R.
Nat Rev Urol. 2014 Mar;11(3):131-2. Epub 2014 Feb 18. No abstract available.

Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden EL, Morgentaler A.
N Engl J Med. 2004 Jan 29;350(5):482-92. Review. No abstract available.

Factors Influencing Prostate-Specific Antigen Response among Men Treated with Testosterone Therapy for 6 Months.
Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.
J Sex Med. 2014 Nov;11(11):2818-25. Epub 2014 Aug 18.

A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M, Crawford D, Morales A, Salonia A, Morgentaler A.
Eur Urol. 2014 Jan;65(1):115-23. Epub 2013 Aug 16. Review.
Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A.
BJU Int. 2014 Jul;114(1):125-30.

Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.
San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A.
BJU Int. 2014 Aug;114(2):229-35. Epub 2014 May 4.

Medical hypothesis: loss of the endocrine function of the prostate is important to the pathophysiology of postprostatectomy erectile dysfunction.
Kacker R, Morgentaler A, Traish A.
J Sex Med. 2014 Aug;11(8):1898-902. Epub 2014 May 16. Review.

Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A.
J Urol. 2013 Jan;189(1 Suppl):S26-33. Review

Testosterone and prostate cancer: what are the risks for middle-aged men?
Morgentaler A.
Urol Clin North Am. 2011 May;38(2):119-24. Epub 2011 Apr 13. Review.

Is testosterone a friend or a foe of the prostate?
Jannini EA, Gravina GL, Morgentaler A, Morales A, Incrocci L, Hellstrom WJ.
J Sex Med. 2011 Apr;8(4):946-55.

Endourologic procedures for benign prostatic hyperplasia: review of indications and outcomes.
Kacker R, Williams SB.
Urol J. 2011 Summer;8(3):171-6. Review

An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: a multicenter study.
Henry GD, Donatucci CF, Conners W, Greenfield JM, Carson CC, Wilson SK, Delk J, Lentz AC, Cleves MA, Jennermann CJ, Kramer AC.
J Sex Med. 2012 Jan;9(1):309-15. Epub 2011 Nov 14.

Occult prostate cancer in men with low serum testosterone levels.
Morgentaler A, Bruning CO 3rd, DeWolf WC.
JAMA. 1996 Dec 18;276(23):1904-6.

Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.
Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D, Jones TH.
Andrology. 2014 Nov;2(6):819-34. Epub 2014 Oct 1.

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
Morgentaler A, McGettigan J, Xiang Q, Danoff TM, Gould EM.
Int J Impot Res. 2014 Jul 24.

Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Kacker R, Hornstein A, Morgentaler A.
Aging Male. 2013 Dec;16(4):164-8. Epub 2013 Oct 3.

The evaluation and management of testosterone deficiency: the new frontier in urology and men’s health.
Conners WP 3rd, Morgentaler A.
Curr Urol Rep. 2013 Dec;14(6):557-64. Review.

Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency.
Kacker R, Traish AM, Morgentaler A.
J Sex Med. 2012 Jun;9(6):1681-96. Epub 2012 Apr 18. Review.

Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy.
Di Sante S, Conners WP, Morgentaler A.
J Sex Med. 2012 Feb;9(2):585-93. Epub 2011 Dec 6.
Commentary: Guideline for male testosterone therapy: a clinician’s perspective.
Morgentaler A.
J Clin Endocrinol Metab. 2007 Feb;92(2):416-7. No abstract available.

Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A.
Andrologia. 2014 Feb 6. doi: 10.1111/and.12237.

Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility.
Kacker R, Conners W, Zade J, Morgentaler A.
J Urol. 2014 Apr;191(4):1072-6. Epub 2013 Oct 23.

Management of impending sterility.
Maranchie J, Morgentaler A.
Lancet. 1996 May 11;347(9011):1344. No abstract available.

Arrow Pointing Up